US6541498B2
(en)
|
1993-05-20 |
2003-04-01 |
Texas Biotechnology |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
HUP0104634A3
(en)
*
|
1998-07-06 |
2002-11-28 |
Bristol Myers Squibb Co |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
MY125533A
(en)
|
1999-12-06 |
2006-08-30 |
Bristol Myers Squibb Co |
Heterocyclic dihydropyrimidine compounds
|
EP1237888B1
(en)
*
|
1999-12-15 |
2006-09-13 |
Bristol-Myers Squibb Company |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
AU2456701A
(en)
*
|
1999-12-31 |
2001-07-16 |
Texas Biotechnology Corporation |
Pharmaceutical and veterinary uses of endothelin antagonists
|
US6271228B1
(en)
*
|
2000-04-28 |
2001-08-07 |
Pfizer Inc. |
Blood pressure stabilization during hemodialysis
|
US7622503B2
(en)
|
2000-08-24 |
2009-11-24 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
WO2002043807A2
(en)
*
|
2000-12-01 |
2002-06-06 |
Novartis Ag |
Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
|
RS51444B
(sr)
|
2001-09-21 |
2011-04-30 |
Bristol-Myers Squibb Company |
JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
MXPA04003553A
(es)
|
2001-10-18 |
2004-07-22 |
Bristol Myers Squibb Co |
Mimeticos del peptido-1 similares aglucagon humano y su uso en tratamiento de diabetes y condiciones relacionadas.
|
US8853266B2
(en)
|
2001-12-06 |
2014-10-07 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators for treating diabetes
|
US6831102B2
(en)
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
TWI328007B
(en)
*
|
2002-01-16 |
2010-08-01 |
Astrazeneca Ab |
Novel compounds
|
TW200307539A
(en)
|
2002-02-01 |
2003-12-16 |
Bristol Myers Squibb Co |
Cycloalkyl inhibitors of potassium channel function
|
TW200403058A
(en)
|
2002-04-19 |
2004-03-01 |
Bristol Myers Squibb Co |
Heterocyclo inhibitors of potassium channel function
|
US7435824B2
(en)
|
2002-04-19 |
2008-10-14 |
Bristol-Myers Squibb Company |
Prodrugs of potassium channel inhibitors
|
US7405234B2
(en)
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7057046B2
(en)
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
MY139563A
(en)
|
2002-09-04 |
2009-10-30 |
Bristol Myers Squibb Co |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
AU2003282983A1
(en)
|
2002-10-23 |
2004-05-13 |
Bristol-Myers Squibb Company |
Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
TW200504021A
(en)
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
US6846836B2
(en)
|
2003-04-18 |
2005-01-25 |
Bristol-Myers Squibb Company |
N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
|
US7557143B2
(en)
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7772232B2
(en)
|
2004-04-15 |
2010-08-10 |
Bristol-Myers Squibb Company |
Quinazolinyl compounds as inhibitors of potassium channel function
|
US7550499B2
(en)
|
2004-05-12 |
2009-06-23 |
Bristol-Myers Squibb Company |
Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
US9884038B2
(en)
|
2004-06-07 |
2018-02-06 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator and methods of use thereof
|
US9889110B2
(en)
|
2004-06-07 |
2018-02-13 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator for treating hormone-related conditions
|
US7145040B2
(en)
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
US7754755B2
(en)
|
2004-09-23 |
2010-07-13 |
Bristol-Myers Squibb Company |
Inhibitors of 15-lipoxygenase
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US7429611B2
(en)
|
2004-09-23 |
2008-09-30 |
Bristol-Myers Squibb Company |
Indole inhibitors of 15-lipoxygenase
|
US7517991B2
(en)
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
US8143425B2
(en)
|
2004-10-12 |
2012-03-27 |
Bristol-Myers Squibb Company |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
US7446210B2
(en)
|
2004-10-26 |
2008-11-04 |
Janssen Pharmaceutica N.V. |
Factor Xa compounds
|
US7589088B2
(en)
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7635699B2
(en)
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
WO2006076598A2
(en)
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
WO2006076569A2
(en)
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7368458B2
(en)
|
2005-01-12 |
2008-05-06 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
WO2006076575A2
(en)
|
2005-01-13 |
2006-07-20 |
Bristol-Myers Squibb Company |
Substituted biaryl compounds as factor xia inhibitors
|
WO2006078697A1
(en)
|
2005-01-18 |
2006-07-27 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
AU2006206611A1
(en)
|
2005-01-19 |
2006-07-27 |
Bristol-Myers Squibb Company |
2-phenoxy-N- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as P2Y1 receptor inhibitors for the treatment of thromboembolic disorders
|
WO2006086464A2
(en)
|
2005-02-10 |
2006-08-17 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones as 5ht modulators
|
EP2527337A1
(en)
|
2005-04-14 |
2012-11-28 |
Bristol-Myers Squibb Company |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
TW200726765A
(en)
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
US7452892B2
(en)
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
US7632837B2
(en)
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
US7629342B2
(en)
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
US7317012B2
(en)
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
EP1899299B1
(en)
|
2005-06-27 |
2010-10-20 |
Bristol-Myers Squibb Company |
C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
WO2007002637A1
(en)
|
2005-06-27 |
2007-01-04 |
Bristol-Myers Squibb Company |
N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
ATE502924T1
(de)
|
2005-06-27 |
2011-04-15 |
Bristol Myers Squibb Co |
Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden
|
WO2007002634A1
(en)
|
2005-06-27 |
2007-01-04 |
Bristol-Myers Squibb Company |
Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
US20070117987A1
(en)
*
|
2005-07-05 |
2007-05-24 |
Viviana Braude |
Process for preparing valsartan
|
EP1757290A1
(en)
|
2005-08-16 |
2007-02-28 |
Zentaris GmbH |
Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
|
US7534804B2
(en)
|
2005-08-24 |
2009-05-19 |
Bristol-Myers Squibb Company |
Benzoxazole inhibitors of 15-lipoxygenase
|
US7795436B2
(en)
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
EA200800710A1
(ru)
|
2005-08-31 |
2008-06-30 |
Юниверсити Оф Теннесси Рисерч Фаундейшн |
Лечение почечной недостаточности, ожогов, ран и повреждений спинного мозга селективными модуляторами андрогенового рецептора
|
AR056155A1
(es)
|
2005-10-26 |
2007-09-19 |
Bristol Myers Squibb Co |
Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
|
WO2007053819A2
(en)
|
2005-10-31 |
2007-05-10 |
Bristol-Myers Squibb Company |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
|
US7553836B2
(en)
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
EP1996588A4
(en)
*
|
2006-03-03 |
2011-10-05 |
Torrent Pharmaceuticals Ltd |
NEW DUAL ACTION RECEPTOR (DARA) ANTAGONISTS OF ATI AND ETA RECEPTORS
|
WO2007109456A2
(en)
*
|
2006-03-16 |
2007-09-27 |
Pharmacopeia, Inc. |
Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists
|
EP2021014A1
(en)
|
2006-05-26 |
2009-02-11 |
Brystol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
JP5215300B2
(ja)
|
2006-07-12 |
2013-06-19 |
ユニバーシティ オブ テネシー リサーチ ファウンデーション |
置換アシルアニリドおよびそれらの使用方法
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
CN101522676A
(zh)
|
2006-10-05 |
2009-09-02 |
Cv医药有限公司 |
用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物
|
US7960569B2
(en)
|
2006-10-17 |
2011-06-14 |
Bristol-Myers Squibb Company |
Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
US9078888B2
(en)
|
2007-01-22 |
2015-07-14 |
Gtx, Inc. |
Nuclear receptor binding agents
|
US9623021B2
(en)
|
2007-01-22 |
2017-04-18 |
Gtx, Inc. |
Nuclear receptor binding agents
|
US9604931B2
(en)
|
2007-01-22 |
2017-03-28 |
Gtx, Inc. |
Nuclear receptor binding agents
|
TW200838501A
(en)
|
2007-02-02 |
2008-10-01 |
Theravance Inc |
Dual-acting antihypertensive agents
|
PE20090185A1
(es)
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
US20080255161A1
(en)
*
|
2007-04-11 |
2008-10-16 |
Dmitry Koltun |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
CN101687873A
(zh)
|
2007-04-17 |
2010-03-31 |
百时美施贵宝公司 |
具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
JP5309131B2
(ja)
|
2007-04-23 |
2013-10-09 |
サノフイ |
P2y12アンタゴニストとしてのキノリン−カルボキサミド誘導体
|
TWI448284B
(zh)
|
2007-04-24 |
2014-08-11 |
Theravance Inc |
雙效抗高血壓劑
|
WO2008137435A1
(en)
|
2007-05-04 |
2008-11-13 |
Bristol-Myers Squibb Company |
[6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
|
WO2008137436A1
(en)
|
2007-05-04 |
2008-11-13 |
Bristol-Myers Squibb Company |
[6,5]-bicyclic gpr119 g protein-coupled receptor agonists
|
TWI406850B
(zh)
|
2007-06-05 |
2013-09-01 |
Theravance Inc |
雙效苯并咪唑抗高血壓劑
|
US20090011994A1
(en)
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
PT2170864E
(pt)
|
2007-07-17 |
2011-11-25 |
Bristol Myers Squibb Co |
Agonistas de receptor acoplado a proteína g gpr119 piridona
|
CN101808995A
(zh)
|
2007-07-27 |
2010-08-18 |
百时美施贵宝公司 |
新颖的葡糖激酶激活剂及其使用方法
|
JP2010538071A
(ja)
|
2007-09-07 |
2010-12-09 |
セラヴァンス, インコーポレーテッド |
二重作用性降圧剤
|
US7968603B2
(en)
|
2007-09-11 |
2011-06-28 |
University Of Tennessee Research Foundation |
Solid forms of selective androgen receptor modulators
|
ES2499018T3
(es)
|
2007-09-20 |
2014-09-26 |
Irm Llc |
Compuestos y composiciones como moduladores de la actividad de GPR119
|
EP2225210B1
(en)
|
2007-12-11 |
2012-04-25 |
Theravance, Inc. |
Dual-acting benzoimidazole derivative and their use as antihypertensive agents
|
EP2238128B1
(en)
|
2007-12-26 |
2012-08-22 |
Sanofi |
Heterocyclic pyrazole-carboxamides as p2y12 antagonists
|
EP2103602A1
(en)
|
2008-03-17 |
2009-09-23 |
AEterna Zentaris GmbH |
Novel 1,2,4-triazole derivatives and process of manufacturing thereof
|
US7989484B2
(en)
|
2008-04-29 |
2011-08-02 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
CA2724430A1
(en)
|
2008-05-19 |
2009-11-26 |
Schering Corporation |
Heterocyclic compounds as factor ixa inhibitors
|
PE20091928A1
(es)
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
WO2009155448A1
(en)
*
|
2008-06-20 |
2009-12-23 |
Ligand Pharmaceuticals Inc. |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
TW201006821A
(en)
|
2008-07-16 |
2010-02-16 |
Bristol Myers Squibb Co |
Pyridone and pyridazone analogues as GPR119 modulators
|
US7863309B2
(en)
|
2008-07-24 |
2011-01-04 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
US20100160322A1
(en)
|
2008-12-04 |
2010-06-24 |
Abbott Laboratories |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US8557983B2
(en)
|
2008-12-04 |
2013-10-15 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US8586754B2
(en)
|
2008-12-05 |
2013-11-19 |
Abbvie Inc. |
BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
US8563735B2
(en)
|
2008-12-05 |
2013-10-22 |
Abbvie Inc. |
Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
EP2409977A4
(en)
*
|
2009-03-17 |
2012-09-26 |
Daiichi Sankyo Co Ltd |
AMIDE DERIVATIVE
|
SG174504A1
(en)
|
2009-03-27 |
2011-10-28 |
Bristol Myers Squibb Co |
Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
|
EP3222277B1
(en)
*
|
2009-03-31 |
2020-02-26 |
Ligand Pharmaceuticals Inc. |
A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis and iga-induced nephropathy
|
CN104876927B
(zh)
|
2009-05-26 |
2017-06-23 |
艾伯维爱尔兰无限公司 |
用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
|
US8546399B2
(en)
|
2009-05-26 |
2013-10-01 |
Abbvie Inc. |
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US9034875B2
(en)
|
2009-05-26 |
2015-05-19 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US20220315555A1
(en)
|
2009-05-26 |
2022-10-06 |
Abbvie Inc. |
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
|
PL2442791T3
(pl)
|
2009-06-16 |
2020-05-18 |
Pfizer Inc. |
Postacie dawkowania apiksabanu
|
US7956054B2
(en)
|
2009-07-07 |
2011-06-07 |
Theravance, Inc. |
Dual-acting pyrazole antihypertensive agents
|
JP2012533626A
(ja)
|
2009-07-22 |
2012-12-27 |
セラヴァンス, インコーポレーテッド |
二重作用オキサゾール降圧剤
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
WO2011017296A1
(en)
|
2009-08-04 |
2011-02-10 |
Schering Corporation |
4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
|
JP2013507366A
(ja)
|
2009-10-09 |
2013-03-04 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Gpr119活性モジュレーターとしての化合物および組成物
|
US20120294936A1
(en)
|
2009-11-13 |
2012-11-22 |
Astrazeneca Uk Limited |
Reduced mass metformin formulations
|
TR201816242T4
(tr)
|
2009-11-13 |
2018-11-21 |
Astrazeneca Ab |
Çabuk salımlı tablet formülasyonları.
|
EP2498758B1
(en)
|
2009-11-13 |
2018-07-25 |
AstraZeneca AB |
Bilayer tablet formulations
|
CN101921265B
(zh)
*
|
2009-11-25 |
2012-07-04 |
北京理工大学 |
联苯酰胺四唑类化合物、合成方法及用途
|
CN101891735B
(zh)
*
|
2009-11-25 |
2012-07-18 |
北京理工大学 |
联苯磺胺异噁唑类化合物、合成方法及用途
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
WO2011090929A1
(en)
|
2010-01-19 |
2011-07-28 |
Theravance, Inc. |
Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
WO2011127106A1
(en)
|
2010-04-08 |
2011-10-13 |
Bristol-Myers Squibb Company |
Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
|
CN102971313A
(zh)
|
2010-04-14 |
2013-03-13 |
百时美施贵宝公司 |
新颖的葡糖激酶激活剂及其使用方法
|
EP2566862B1
(en)
|
2010-05-06 |
2015-09-16 |
Bristol-Myers Squibb Company |
Benzofuranyl analogues as gpr119 modulators
|
EA201270778A1
(ru)
|
2010-05-06 |
2013-04-30 |
Бристол-Майерс Сквибб Компани |
Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
EP2431035A1
(en)
|
2010-09-16 |
2012-03-21 |
Æterna Zentaris GmbH |
Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
|
RU2598345C2
(ru)
|
2010-10-29 |
2016-09-20 |
Эббви Инк. |
Твердые дисперсии, содержащие средства, вызывающие апоптоз
|
UA113500C2
(xx)
|
2010-10-29 |
2017-02-10 |
|
Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
|
ES2644230T3
(es)
|
2010-11-23 |
2017-11-28 |
Abbvie Inc. |
Sales y formas cristalinas de un agente inductor de apoptosis
|
EP2642999B1
(en)
|
2010-11-23 |
2016-09-28 |
AbbVie Bahamas Ltd. |
Methods of treatment using selective bcl-2 inhibitors
|
AU2011346758C1
(en)
|
2010-12-23 |
2015-09-03 |
Purdue Pharma L.P. |
Tamper resistant solid oral dosage forms
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
BR112014011254A2
(pt)
|
2011-11-11 |
2017-05-16 |
Pfizer |
2-tiopirimidinonas
|
US9296745B2
(en)
|
2012-04-06 |
2016-03-29 |
Pfizer Inc. |
Diacylglycerol acyltransferase 2 inhibitors
|
WO2013173198A1
(en)
|
2012-05-16 |
2013-11-21 |
Bristol-Myers Squibb Company |
Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
|
AU2013274619B2
(en)
|
2012-06-11 |
2017-09-28 |
Bristol-Myers Squibb Company |
Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide
|
US9622992B2
(en)
|
2012-07-13 |
2017-04-18 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US9744149B2
(en)
|
2012-07-13 |
2017-08-29 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
JP6226978B2
(ja)
|
2012-07-13 |
2017-11-08 |
ジーティーエックス・インコーポレイテッド |
選択的アンドロゲン受容体モジュレーター(sarm)によりアンドロゲン受容体(ar)陽性乳癌を処置する方法
|
US10987334B2
(en)
|
2012-07-13 |
2021-04-27 |
University Of Tennessee Research Foundation |
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
|
US10314807B2
(en)
|
2012-07-13 |
2019-06-11 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US10258596B2
(en)
|
2012-07-13 |
2019-04-16 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US9969683B2
(en)
|
2012-07-13 |
2018-05-15 |
Gtx, Inc. |
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
|
LT6043B
(lt)
|
2012-08-27 |
2014-06-25 |
Uab "Mibarsas" |
Organinės trąšos sapropelio pagrindu ir jų gamybos būdas
|
EP2892896B1
(en)
|
2012-09-05 |
2016-06-29 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
|
EP2892897A1
(en)
|
2012-09-05 |
2015-07-15 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
US9200025B2
(en)
|
2012-11-20 |
2015-12-01 |
Lexicon Pharmaceuticals, Inc. |
Inhibitors of sodium glucose cotransporter 1
|
US9242966B2
(en)
|
2013-03-11 |
2016-01-26 |
Bristol-Myers Squibb Company |
Phthalazines as potassium ion channel inhibitors
|
CN105008366B
(zh)
|
2013-03-11 |
2017-11-14 |
百时美施贵宝公司 |
作为钾离子通道抑制剂的吡咯并哒嗪类化合物
|
CN105008347A
(zh)
|
2013-03-11 |
2015-10-28 |
百时美施贵宝公司 |
作为钾离子通道抑制剂的异喹啉类化合物
|
US9050345B2
(en)
|
2013-03-11 |
2015-06-09 |
Bristol-Myers Squibb Company |
Pyrrolotriazines as potassium ion channel inhibitors
|
JP6395798B2
(ja)
|
2013-03-11 |
2018-09-26 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
カリウムイオンチャネル阻害剤としてのピロロトリアジン
|
US20140275082A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US9732074B2
(en)
*
|
2013-03-15 |
2017-08-15 |
University Of Southern California |
Methods, compounds, and compositions for the treatment of angiotensin-related diseases
|
JP6348582B2
(ja)
|
2013-10-09 |
2018-06-27 |
ファイザー・インク |
プロスタグランジンep3受容体の拮抗薬
|
US9580422B2
(en)
|
2013-10-22 |
2017-02-28 |
Bristol-Myers Squibb Company |
Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
ES2674240T3
(es)
|
2014-03-17 |
2018-06-28 |
Pfizer Inc. |
Inhibidores de diacilglicerol aciltransferasa 2 para su uso en el tratamiento de trastornos metabólicos y relacionados
|
RS63024B1
(sr)
|
2014-04-04 |
2022-04-29 |
Pfizer |
Kondenzovana biciklična heteroaril ili aril jedinjenja i njihova upotreba kao irak4 inhibitora
|
WO2015160636A1
(en)
|
2014-04-16 |
2015-10-22 |
Merck Sharp & Dohme Corp. |
Factor ixa inhibitors
|
MX2016015467A
(es)
|
2014-05-30 |
2017-03-23 |
Pfizer |
Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos.
|
JP2017538769A
(ja)
|
2014-12-22 |
2017-12-28 |
ファイザー・インク |
プロスタグランジンep3受容体の拮抗薬
|
CN104761548B
(zh)
*
|
2015-04-27 |
2017-09-12 |
梯尔希(南京)药物研发有限公司 |
一种稳定同位素标记的二苯基磺酰胺类药物的制备方法
|
CN107531647A
(zh)
|
2015-05-05 |
2018-01-02 |
辉瑞大药厂 |
2‑硫代嘧啶酮类
|
CA2987179C
(en)
|
2015-05-29 |
2020-08-25 |
Pfizer Inc. |
Heterocyclic compounds as inhibitors of vanin-1 enzyme
|
PE20180478A1
(es)
|
2015-06-17 |
2018-03-07 |
Pfizer |
Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
CA2995153A1
(en)
|
2015-08-13 |
2017-02-16 |
Pfizer Inc. |
Bicyclic-fused heteroaryl or aryl compounds
|
RU2684324C1
(ru)
|
2015-08-27 |
2019-04-08 |
Пфайзер Инк. |
Бициклические конденсированные гетероарильные или арильные соединения в качестве модуляторов IRAK4
|
WO2017037567A1
(en)
|
2015-09-03 |
2017-03-09 |
Pfizer Inc. |
Regulators of frataxin
|
CN105481844A
(zh)
*
|
2015-12-08 |
2016-04-13 |
梁彦云 |
一种治疗高血压的药物组合物
|
GEP20207147B
(en)
|
2015-12-29 |
2020-09-10 |
Pfizer |
Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
|
CN106188115A
(zh)
*
|
2016-07-13 |
2016-12-07 |
北京理工大学 |
廉价高效合成2‑二羟硼基‑n‑二甲异噁唑基‑n‑甲氧乙氧甲基苯磺酰胺的新方法
|
US10906888B2
(en)
|
2016-07-14 |
2021-02-02 |
Pfizer Inc. |
Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
|
EP3487862A1
(en)
|
2016-07-22 |
2019-05-29 |
Bristol-Myers Squibb Company |
Glucokinase activators and methods of using same
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
CN116983302A
(zh)
|
2016-10-13 |
2023-11-03 |
特拉维尔治疗公司 |
用于治疗肾脏疾病或病症的联苯磺酰胺化合物
|
US10703723B2
(en)
|
2017-03-09 |
2020-07-07 |
Truly Translational Sweden Ab |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
PL3630188T3
(pl)
|
2017-05-31 |
2022-01-03 |
Amplio Pharma Ab |
Kompozycja farmaceutyczna zawierająca kombinację metotreksatu i nowobiocyny oraz zastosowanie wspomnianej kompozycji w terapii
|
FI3488868T3
(fi)
|
2017-11-23 |
2023-10-20 |
Medac Ges Fuer Klinische Spezialpraeparate Mbh |
Suun kautta annettava sulfasalatsiinia ja/tai sulfasalatsiinin orgaanista suolaa sisältävä farmaseuttinen koostumus, valmistusmenetelmä ja käyttö
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
US11752173B2
(en)
|
2017-12-19 |
2023-09-12 |
Beijing Jiyuan Biological Technology Co., Ltd. |
FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease
|
WO2019133445A1
(en)
|
2017-12-28 |
2019-07-04 |
Inception Ibd, Inc. |
Aminothiazoles as inhibitors of vanin-1
|
MX2021000601A
(es)
|
2018-07-19 |
2021-04-13 |
Astrazeneca Ab |
Metodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma.
|
TWI718644B
(zh)
|
2018-08-31 |
2021-02-11 |
美商輝瑞股份有限公司 |
用於治療nash/nafld和相關疾病之組合
|
CN113039176A
(zh)
|
2018-09-26 |
2021-06-25 |
莱西肯医药有限公司 |
N-(1-((2-(二甲基氨基)乙基)氨基)-2-甲基-1-氧代丙-2-基)-4-(4-(2-甲基-5-((2s,3r,4r,5s,6r)-3,4,5-三羟基-6-(甲硫基)四氢-2h-吡喃-2-基)苯甲基)苯基)丁酰胺的结晶形式及其合成方法
|
BR112021006132A2
(pt)
|
2018-10-04 |
2021-07-20 |
Travere Therapeutics, Inc. |
compostos bifenil sulfonamida para o tratamento de doenças de colágeno tipo iv
|
WO2020102575A1
(en)
|
2018-11-16 |
2020-05-22 |
Inception Ibd, Inc. |
Heterocyclic aminothiazoles and uses thereof
|
CN113874019A
(zh)
|
2019-05-20 |
2021-12-31 |
辉瑞大药厂 |
用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合
|
JP7498199B2
(ja)
|
2019-06-28 |
2024-06-11 |
ファイザー・インク |
種々の疾患を処置するために有用なbckdk阻害剤としての5-(チオフェン-2-イル)-1h-テトラゾール誘導体
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
PE20231215A1
(es)
|
2020-06-09 |
2023-08-17 |
Pfizer |
Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos
|
US20220023252A1
(en)
|
2020-07-27 |
2022-01-27 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
WO2022266370A1
(en)
|
2021-06-17 |
2022-12-22 |
Aria Pharmaceuticals, Inc. |
Sparsentan for treating idiopathic pulmonary fibrosis
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|
WO2023026180A1
(en)
|
2021-08-26 |
2023-03-02 |
Pfizer Inc. |
Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
|
AU2022334402A1
(en)
*
|
2021-08-26 |
2024-02-22 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Aromatic ring-containing biological antagonist, and preparation method therefor and use thereof
|
CA3235437A1
(en)
*
|
2021-10-21 |
2023-04-27 |
Ji Ma |
Dual antagonist and use thereof
|
WO2023100061A1
(en)
|
2021-12-01 |
2023-06-08 |
Pfizer Inc. |
3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
WO2023144722A1
(en)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|
WO2023169456A1
(en)
|
2022-03-09 |
2023-09-14 |
Gasherbrum Bio , Inc. |
Heterocyclic glp-1 agonists
|
WO2023198140A1
(en)
|
2022-04-14 |
2023-10-19 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
WO2023224963A1
(en)
*
|
2022-05-16 |
2023-11-23 |
Aria Pharmaceuticals, Inc. |
Dual-acting angiotensin and endothelin receptor antagonists
|
WO2024075051A1
(en)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|
US20240182468A1
(en)
|
2022-10-18 |
2024-06-06 |
Pfizer Inc. |
Compounds for the activation of ampk
|
WO2024084360A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
|
CN115745983A
(zh)
*
|
2022-11-23 |
2023-03-07 |
深圳信立泰药业股份有限公司 |
一种血管紧张肽和内皮肽受体拮抗剂及其应用
|
WO2024125602A1
(en)
|
2022-12-15 |
2024-06-20 |
Gasherbrum Bio, Inc. |
Salts and solid forms of a compound having glp-1 agonist activity
|
WO2024127297A1
(en)
|
2022-12-16 |
2024-06-20 |
Pfizer Inc. |
3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof
|